BCIRG 007: Serum HER2 levels in women with metastatic HER2-amplified breast cancer

被引：0
|
作者：
Sampson, E. L.
Valero, V.
Roche, H.
Pienkowski, T.
Canon, J.
Zhao, Y.
Carney, W.
Mackey, J.
Taupin, H.
Lindsay, M.
Buyse, M.
Slamon, D.
机构：
[1] Siemens Med Solut Diagnost, Tarrytown, NY USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Inst Claudius Regaud, Toulouse, France
[4] MS Curie Mem Canc Ctr, Warsaw, Poland
[5] CH Notre Dame, Charleroi, Belgium
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[8] CIRG, Paris, France
[9] CIRG, Edmonton, AB, Canada
[10] IDDI, Louvain, Belgium
来源：
CLINICAL CHEMISTRY | 2007年 / 53卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
A109
引用
收藏
页码：A34 / A34
页数：1
相关论文
共 50 条
  • [21] Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Stiller, Tracey
    Blanchard, M. Suzette
    Padam, Simran
    Katheria, Vani
    Kim, Heeyoung
    Sun, Canlan
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Dipesh
    Sedrak, Mina S.
    Waisman, James
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 752 - 758
  • [22] Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
    Cocco, Emiliano
    Carmona, F. Javier
    Won, Helen H.
    Berger, Michael F.
    Hyman, David M.
    Rossi, Valentina
    Chan, Carmen
    Moriarty, Alyssa
    Papadopoulos, Kyriakos P.
    Wick, Michael J.
    Cownie, James
    Sarotto, Ivana
    Cutler, Richard E.
    Avogadri-Connors, Francesca
    Savas, Peter
    Lalani, Alshad S.
    Boni, Valentina
    Loi, Sherene
    Baselga, Jose
    Montemurro, Filippo
    Scaltriti, Maurizio
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [23] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Verschoor, Noortje
    Smid, Marcel
    Jager, Agnes
    Sleijfer, Stefan
    Wilting, Saskia M.
    Martens, John W. M.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [24] Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
    Noortje Verschoor
    Marcel Smid
    Agnes Jager
    Stefan Sleijfer
    Saskia M. Wilting
    John W. M. Martens
    Breast Cancer Research, 25
  • [25] The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
    Boer R.
    Breast Cancer Research, 1 (1)
  • [26] HER2-amplified gastric and colorectal cancers: Mechanistic insights into HER2 targeting approaches
    Leto, Simonetta Maria
    Sassi, Francesco
    Migliardi, Giorgia
    Zanella, Eugenia
    Catalano, Irene
    Bertotti, Andrea
    Trusolino, Livio
    CLINICAL CANCER RESEARCH, 2015, 21
  • [27] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [28] Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
    Vivien H. C. Bramwell
    Gordon S. Doig
    Alan B. Tuck
    Sylvia M. Wilson
    Katia S. Tonkin
    Anna Tomiak
    Francisco Perera
    Theodore A. Vandenberg
    Ann F. Chambers
    Breast Cancer Research and Treatment, 2009, 114
  • [29] Anthracycline-free therapy for HER2-amplified breast cancer
    Gennari, Alessandra
    Del Mastro, Lucia
    LANCET ONCOLOGY, 2013, 14 (11): : 1037 - 1038
  • [30] Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
    Bramwell, Vivien H. C.
    Doig, Gordon S.
    Tuck, Alan B.
    Wilson, Sylvia M.
    Tonkin, Katia S.
    Tomiak, Anna
    Perera, Francisco
    Vandenberg, Theodore A.
    Chambers, Ann F.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 503 - 511
12345